Loading…

Effects of replacement fluids on coagulation system used for therapeutic plasma exchange

Therapeutic apheresis is a widely used treatment alternative for several diseases. In 29 patients with different diseases, we have monitored the PT, aPTT, thrombin time (TT), fibrinogen, D-dimer, factor VIII, IX, X, XI, XII, VWF, Protein C, S, Active Protein C Resistance (APCR) and Antithrombin-III...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion and apheresis science 2003-02, Vol.28 (1), p.3-7
Main Authors: Tek, Ibrahim, Arslan, Önder, Arat, Mutlu, Özcan, Muhit, Akdağ, Beyza, İlhan, Osman
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c361t-68cc9c8d155333431b85f81715f1d507ccd9c2a1d69e626cbcf1a58bd14dc3a53
cites cdi_FETCH-LOGICAL-c361t-68cc9c8d155333431b85f81715f1d507ccd9c2a1d69e626cbcf1a58bd14dc3a53
container_end_page 7
container_issue 1
container_start_page 3
container_title Transfusion and apheresis science
container_volume 28
creator Tek, Ibrahim
Arslan, Önder
Arat, Mutlu
Özcan, Muhit
Akdağ, Beyza
İlhan, Osman
description Therapeutic apheresis is a widely used treatment alternative for several diseases. In 29 patients with different diseases, we have monitored the PT, aPTT, thrombin time (TT), fibrinogen, D-dimer, factor VIII, IX, X, XI, XII, VWF, Protein C, S, Active Protein C Resistance (APCR) and Antithrombin-III during TPE. Patients were divided into four groups based on the replacement fluids used: 3% VARIHES or ISOHES+4% albumin (1:1) (group 1), fresh frozen plasma (FFP) (group 2), 3% VARIHES or ISOHES (group 3) and 4% albumin (group 4). In our study, the fibrinogen level decreased to 83% of the base line level after the end of 48 h therapy. The APTT, PT, and TT increased during TPE. However no statistical difference was observed between the groups. We found a significant change in factor levels with time, only the difference in factors IX and XI between the groups was significant. In addition, factor levels measured at 48 h were close to the levels measured before aphereses. In our study, time the related change in AT-3 values was significant. Time-related changes of the Protein S and APCR were not statistical significant significant but on the other hand, we found a significant difference in AT-III and Protein C values between groups. The side effects of HES on coagulation factors and tests were comparable to those of other replacement fluids. Its low cost makes it favourable.
doi_str_mv 10.1016/S1473-0502(02)00093-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73074493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473050202000939</els_id><sourcerecordid>73074493</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-68cc9c8d155333431b85f81715f1d507ccd9c2a1d69e626cbcf1a58bd14dc3a53</originalsourceid><addsrcrecordid>eNqFkE1r3DAQhkVoyGd_QotOJTk40ViWbJ9KCZsPCOSQFnIT2tFoo-KPrWSH5t9H293QY0BCg3jeGelh7AuICxCgLx-hqmUhlCjPRHkuhGhl0e6xI2jqpgDdyE-5fkcO2XFKv4WAGlp9wA6h1KXI-4g9LbwnnBIfPY-07ixST8PEfTcHl28HjqNdzZ2dQq7Ta5qo53Mix_0Y-fRM0a5pngLynE295fQXn-2wolO2722X6PPuPGG_rhc_r26L-4ebu6sf9wVKDVOhG8QWGwdKSSkrCctG-Sa_U3lwStSIrsXSgtMt6VLjEj1Y1SwdVA6lVfKEfdv2Xcfxz0xpMn1ISF1nBxrnZGop6qpqZQbVFsQ4phTJm3UMvY2vBoTZKDX_lJqNL7NZG6WmzbmvuwHzsif3P7VzmIHvW4DyN18CRZMw0IDkQsxqjRvDByPeACCAhtw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73074493</pqid></control><display><type>article</type><title>Effects of replacement fluids on coagulation system used for therapeutic plasma exchange</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Tek, Ibrahim ; Arslan, Önder ; Arat, Mutlu ; Özcan, Muhit ; Akdağ, Beyza ; İlhan, Osman</creator><creatorcontrib>Tek, Ibrahim ; Arslan, Önder ; Arat, Mutlu ; Özcan, Muhit ; Akdağ, Beyza ; İlhan, Osman</creatorcontrib><description>Therapeutic apheresis is a widely used treatment alternative for several diseases. In 29 patients with different diseases, we have monitored the PT, aPTT, thrombin time (TT), fibrinogen, D-dimer, factor VIII, IX, X, XI, XII, VWF, Protein C, S, Active Protein C Resistance (APCR) and Antithrombin-III during TPE. Patients were divided into four groups based on the replacement fluids used: 3% VARIHES or ISOHES+4% albumin (1:1) (group 1), fresh frozen plasma (FFP) (group 2), 3% VARIHES or ISOHES (group 3) and 4% albumin (group 4). In our study, the fibrinogen level decreased to 83% of the base line level after the end of 48 h therapy. The APTT, PT, and TT increased during TPE. However no statistical difference was observed between the groups. We found a significant change in factor levels with time, only the difference in factors IX and XI between the groups was significant. In addition, factor levels measured at 48 h were close to the levels measured before aphereses. In our study, time the related change in AT-3 values was significant. Time-related changes of the Protein S and APCR were not statistical significant significant but on the other hand, we found a significant difference in AT-III and Protein C values between groups. The side effects of HES on coagulation factors and tests were comparable to those of other replacement fluids. Its low cost makes it favourable.</description><identifier>ISSN: 1473-0502</identifier><identifier>EISSN: 1878-1683</identifier><identifier>DOI: 10.1016/S1473-0502(02)00093-9</identifier><identifier>PMID: 12620262</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Blood Coagulation - drug effects ; Blood Coagulation Factor Inhibitors - analysis ; Blood Coagulation Factors - analysis ; Blood Coagulation Tests ; Blood Substitutes - pharmacology ; Coagulation factors ; Female ; Health technology assessment ; Humans ; Hydroxyethyl Starch Derivatives - pharmacology ; Male ; Middle Aged ; Plasma ; Plasma exchange ; Plasma Exchange - methods ; Plasma Exchange - standards ; Replacement solutions ; Serum Albumin - pharmacology ; Time Factors</subject><ispartof>Transfusion and apheresis science, 2003-02, Vol.28 (1), p.3-7</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>Copyright 2003 Elsevier Science Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-68cc9c8d155333431b85f81715f1d507ccd9c2a1d69e626cbcf1a58bd14dc3a53</citedby><cites>FETCH-LOGICAL-c361t-68cc9c8d155333431b85f81715f1d507ccd9c2a1d69e626cbcf1a58bd14dc3a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12620262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tek, Ibrahim</creatorcontrib><creatorcontrib>Arslan, Önder</creatorcontrib><creatorcontrib>Arat, Mutlu</creatorcontrib><creatorcontrib>Özcan, Muhit</creatorcontrib><creatorcontrib>Akdağ, Beyza</creatorcontrib><creatorcontrib>İlhan, Osman</creatorcontrib><title>Effects of replacement fluids on coagulation system used for therapeutic plasma exchange</title><title>Transfusion and apheresis science</title><addtitle>Transfus Apher Sci</addtitle><description>Therapeutic apheresis is a widely used treatment alternative for several diseases. In 29 patients with different diseases, we have monitored the PT, aPTT, thrombin time (TT), fibrinogen, D-dimer, factor VIII, IX, X, XI, XII, VWF, Protein C, S, Active Protein C Resistance (APCR) and Antithrombin-III during TPE. Patients were divided into four groups based on the replacement fluids used: 3% VARIHES or ISOHES+4% albumin (1:1) (group 1), fresh frozen plasma (FFP) (group 2), 3% VARIHES or ISOHES (group 3) and 4% albumin (group 4). In our study, the fibrinogen level decreased to 83% of the base line level after the end of 48 h therapy. The APTT, PT, and TT increased during TPE. However no statistical difference was observed between the groups. We found a significant change in factor levels with time, only the difference in factors IX and XI between the groups was significant. In addition, factor levels measured at 48 h were close to the levels measured before aphereses. In our study, time the related change in AT-3 values was significant. Time-related changes of the Protein S and APCR were not statistical significant significant but on the other hand, we found a significant difference in AT-III and Protein C values between groups. The side effects of HES on coagulation factors and tests were comparable to those of other replacement fluids. Its low cost makes it favourable.</description><subject>Adult</subject><subject>Aged</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood Coagulation Factor Inhibitors - analysis</subject><subject>Blood Coagulation Factors - analysis</subject><subject>Blood Coagulation Tests</subject><subject>Blood Substitutes - pharmacology</subject><subject>Coagulation factors</subject><subject>Female</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Hydroxyethyl Starch Derivatives - pharmacology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Plasma</subject><subject>Plasma exchange</subject><subject>Plasma Exchange - methods</subject><subject>Plasma Exchange - standards</subject><subject>Replacement solutions</subject><subject>Serum Albumin - pharmacology</subject><subject>Time Factors</subject><issn>1473-0502</issn><issn>1878-1683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkE1r3DAQhkVoyGd_QotOJTk40ViWbJ9KCZsPCOSQFnIT2tFoo-KPrWSH5t9H293QY0BCg3jeGelh7AuICxCgLx-hqmUhlCjPRHkuhGhl0e6xI2jqpgDdyE-5fkcO2XFKv4WAGlp9wA6h1KXI-4g9LbwnnBIfPY-07ixST8PEfTcHl28HjqNdzZ2dQq7Ta5qo53Mix_0Y-fRM0a5pngLynE295fQXn-2wolO2722X6PPuPGG_rhc_r26L-4ebu6sf9wVKDVOhG8QWGwdKSSkrCctG-Sa_U3lwStSIrsXSgtMt6VLjEj1Y1SwdVA6lVfKEfdv2Xcfxz0xpMn1ISF1nBxrnZGop6qpqZQbVFsQ4phTJm3UMvY2vBoTZKDX_lJqNL7NZG6WmzbmvuwHzsif3P7VzmIHvW4DyN18CRZMw0IDkQsxqjRvDByPeACCAhtw</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>Tek, Ibrahim</creator><creator>Arslan, Önder</creator><creator>Arat, Mutlu</creator><creator>Özcan, Muhit</creator><creator>Akdağ, Beyza</creator><creator>İlhan, Osman</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030201</creationdate><title>Effects of replacement fluids on coagulation system used for therapeutic plasma exchange</title><author>Tek, Ibrahim ; Arslan, Önder ; Arat, Mutlu ; Özcan, Muhit ; Akdağ, Beyza ; İlhan, Osman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-68cc9c8d155333431b85f81715f1d507ccd9c2a1d69e626cbcf1a58bd14dc3a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood Coagulation Factor Inhibitors - analysis</topic><topic>Blood Coagulation Factors - analysis</topic><topic>Blood Coagulation Tests</topic><topic>Blood Substitutes - pharmacology</topic><topic>Coagulation factors</topic><topic>Female</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Hydroxyethyl Starch Derivatives - pharmacology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Plasma</topic><topic>Plasma exchange</topic><topic>Plasma Exchange - methods</topic><topic>Plasma Exchange - standards</topic><topic>Replacement solutions</topic><topic>Serum Albumin - pharmacology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tek, Ibrahim</creatorcontrib><creatorcontrib>Arslan, Önder</creatorcontrib><creatorcontrib>Arat, Mutlu</creatorcontrib><creatorcontrib>Özcan, Muhit</creatorcontrib><creatorcontrib>Akdağ, Beyza</creatorcontrib><creatorcontrib>İlhan, Osman</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion and apheresis science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tek, Ibrahim</au><au>Arslan, Önder</au><au>Arat, Mutlu</au><au>Özcan, Muhit</au><au>Akdağ, Beyza</au><au>İlhan, Osman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of replacement fluids on coagulation system used for therapeutic plasma exchange</atitle><jtitle>Transfusion and apheresis science</jtitle><addtitle>Transfus Apher Sci</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>28</volume><issue>1</issue><spage>3</spage><epage>7</epage><pages>3-7</pages><issn>1473-0502</issn><eissn>1878-1683</eissn><abstract>Therapeutic apheresis is a widely used treatment alternative for several diseases. In 29 patients with different diseases, we have monitored the PT, aPTT, thrombin time (TT), fibrinogen, D-dimer, factor VIII, IX, X, XI, XII, VWF, Protein C, S, Active Protein C Resistance (APCR) and Antithrombin-III during TPE. Patients were divided into four groups based on the replacement fluids used: 3% VARIHES or ISOHES+4% albumin (1:1) (group 1), fresh frozen plasma (FFP) (group 2), 3% VARIHES or ISOHES (group 3) and 4% albumin (group 4). In our study, the fibrinogen level decreased to 83% of the base line level after the end of 48 h therapy. The APTT, PT, and TT increased during TPE. However no statistical difference was observed between the groups. We found a significant change in factor levels with time, only the difference in factors IX and XI between the groups was significant. In addition, factor levels measured at 48 h were close to the levels measured before aphereses. In our study, time the related change in AT-3 values was significant. Time-related changes of the Protein S and APCR were not statistical significant significant but on the other hand, we found a significant difference in AT-III and Protein C values between groups. The side effects of HES on coagulation factors and tests were comparable to those of other replacement fluids. Its low cost makes it favourable.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12620262</pmid><doi>10.1016/S1473-0502(02)00093-9</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1473-0502
ispartof Transfusion and apheresis science, 2003-02, Vol.28 (1), p.3-7
issn 1473-0502
1878-1683
language eng
recordid cdi_proquest_miscellaneous_73074493
source ScienceDirect Freedom Collection 2022-2024
subjects Adult
Aged
Blood Coagulation - drug effects
Blood Coagulation Factor Inhibitors - analysis
Blood Coagulation Factors - analysis
Blood Coagulation Tests
Blood Substitutes - pharmacology
Coagulation factors
Female
Health technology assessment
Humans
Hydroxyethyl Starch Derivatives - pharmacology
Male
Middle Aged
Plasma
Plasma exchange
Plasma Exchange - methods
Plasma Exchange - standards
Replacement solutions
Serum Albumin - pharmacology
Time Factors
title Effects of replacement fluids on coagulation system used for therapeutic plasma exchange
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A21%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20replacement%20fluids%20on%20coagulation%20system%20used%20for%20therapeutic%20plasma%20exchange&rft.jtitle=Transfusion%20and%20apheresis%20science&rft.au=Tek,%20Ibrahim&rft.date=2003-02-01&rft.volume=28&rft.issue=1&rft.spage=3&rft.epage=7&rft.pages=3-7&rft.issn=1473-0502&rft.eissn=1878-1683&rft_id=info:doi/10.1016/S1473-0502(02)00093-9&rft_dat=%3Cproquest_cross%3E73074493%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c361t-68cc9c8d155333431b85f81715f1d507ccd9c2a1d69e626cbcf1a58bd14dc3a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73074493&rft_id=info:pmid/12620262&rfr_iscdi=true